Nelarabine

Nelarabine
Clinical data
Trade names	Arranon, Atriance
Other names	506U78
AHFS/Drugs.com	Monograph
MedlinePlus	a607077
License data	EU EMA: by INN; US DailyMed: Nelarabine; US FDA: Nelarabine;
Routes of; administration	Intravenous
ATC code	L01BB07 (WHO) ;
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	<25%
Metabolism	By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Elimination half-life	30 minutes (nelarabine); 3 hours (ara-G)
Excretion	Kidney
Identifiers
CAS Number	121032-29-9 ;
PubChem CID	3011155;
IUPHAR/BPS	7090;
DrugBank	DB01280 ;
ChemSpider	2280207 ;
UNII	60158CV180;
KEGG	D05134 ;
ChEMBL	ChEMBL1201112 ;
CompTox Dashboard (EPA)	DTXSID6046842 ;
ECHA InfoCard	100.170.768
Chemical and physical data
Formula	C11H15N5O5
Molar mass	297.271 g·mol−1
3D model (JSmol)	Interactive image;
	show SMILES
	show InChI
	(what is this?)

Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and (T-LBL).

Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.^[3] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.^[4] It was later approved in the European Union in October 2005. Complete responses have been achieved with this medication.^{[medical citation needed]}

References[]

^ "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.
^ "Atriance EPAR". European Medicines Agency (EMA). Retrieved 4 December 2020.
^ "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.
^ Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926.

External links[]

"Nelarabine". Drug Information Portal. U.S. National Library of Medicine.
"Nelarabine". NCI Dictionary of Cancer Terms. National Cancer Institute.
"Nelarabine". National Cancer Institute.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[Arranon_FDA_label-1] "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.

[Atriance_EPAR-2] "Atriance EPAR". European Medicines Agency (EMA). Retrieved 4 December 2020.

[3] "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.

[Example2006a-4] Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926.

[1]

[2]

[3]

[4]